New pill for diabetes shows promise in Real-World study
NCT ID NCT06269120
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow about 470 adults with type 2 diabetes who are starting oral semaglutide as part of their normal care. Researchers will track changes in blood sugar (HbA1c) and body weight over 5 to 7 months. The goal is to see how well the medication works when prescribed by cardiologists or diabetologists in everyday practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral semaglutide
What this could lead to
If successful, this could show that oral semaglutide helps many patients with type 2 diabetes achieve better blood sugar control and weight loss in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also short-term (5-7 months) and may not reflect long-term benefits or risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Siklósi Kórház, Diabetológia
RECRUITINGSiklós, 7801, Hungary